aldose reductase inhibitor


Also found in: Acronyms, Wikipedia.

aldose reductase inhibitor

Any of a family of compounds (e.g., epalrestat, ponalrestat, sorbinil, tolrestat) that block aldose reductase, which catalyses the reduction of glucose to sorbitol; accumulation of polyols through the autosomal recessive pathway is believed to lead to microvascular and neurologic complications of diabetes. Increased intracellular glucose leads to increased sorbitol, which competitively inhibits glomerular and neural synthesis of myo-inositol; the decrease in myo-inositol synthesis depresses phosphoinositide metabolism and reduces Na+K+-ATPase activity. ARIs do not prevent the complications of type-1 diabetes.

aldose reductase inhibitor

Clinical therapeutics Any of a family of compounds–eg, epalrestat, ponalrestat, sorbinil, tolrestat, which block aldose reductase; ↑ intracellular glucose leads to ↑ sorbitol, which competitively inhibits glomerular and neural synthesis of myo-inositol; the ↓ in myo-inositol synthesis depresses phosphoinositide metabolism, and ↓ in Na+K+-ATPase activity; ARIs do not prevent the complications of type 1 DM See Aldose reductase.
References in periodicals archive ?
On contrary, cells treated with aldose reductase inhibitors had a much lower rate of apoptosis, reduced levels of reactive oxygen species, far smaller increases in critical transcription factors and substantially lower increases in inflammatory signaling molecules.
Srivastava next investigated whether aldose reductase inhibitors could reduce the asthma-like symptoms of mice exposed to ragweed extract, a well-established clinical model mimicking the allergic airway inflammation that commonly leads to asthma in humans.
Srivastava said that the next step will be clinical trials to determine whether aldose reductase inhibitors can relieve asthma in humans.
Aldose reductase inhibitors can block the polyol pathway and have been used to deliberate the development of diabetic cardiovascular autonomic neuropathy (DCAN).
In the course of our investigation for potential aldose reductase inhibitors from natural sources, we focused on G.
Due to the limited number of currently available aldose reductase inhibitors, the result of our present study is significant for isolating a natural product that can potentially be optimized as an aldose reductase inhibitors.
Diabetic-like retinopathy in rat prevented with an aldose reductase Inhibitor.
A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy.
Aldose reductase inhibitors have considerable potential for the treatment of diabetic complications, without increased risk of hypoglycemia.
Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
Effects of a new aldose reductase inhibitor on various tissues in vitro.
aegyptiaca or some of its components may act, at least in part, as aldose reductase inhibitors.